Nov 03, 2025
A drug-reformulation platform giving existing molecules a new therapeutic life.
Through long-acting intranasal delivery, designed for chronic respiratory and CNS diseases.
Mastering innovation to enhance patients and caregivers quality of life.
Scroll down
UNMET NEEDS / PAIN POINTS
Where current treatments fall short
A massive global burden
- Allergic rhinitis — 1.4 billion patients worldwide¹
- Chronic rhinosinusitis — 900 million patients impacted²
- CNS disorders — 35 million patients (schizophrenia + Parkinson’s)³
- Non-compliance — 85% of allergic rhinitis patients are not compliant with their daily treatment⁴
- Non-response — 20–25% of CRS patients do not respond to first-line treatment⁵
- Drug-delivery barriers — major obstacles (BBB, hepatic first-pass) limit CNS treatment efficacy
A treatment gap that persists
About us
Our ambitions
Dianosic designs transformative long-acting resorbable intranasal solid-dosage forms to overcome the delivery challenges of chronic respiratory and CNS therapies.
We identify unmet clinical needs with healthcare professionals and collaborate with them to offer disruptive solutions to the patients, the medical community and the society as a whole.
The administration of long-acting intranasal solid dosage forms enables the treatment of multiple respiratory diseases at low doses, delivered directly at the site of action.
Addresses a major challenge in patient adherence to treatment.
For central nervous system disorders, this approach has the potential to overcome major drug-delivery barriers by exploiting the “nose-to-brain” pathway.
Excellent nasal retention without compromising patient comfort or quality of life.
Our Science
Dianosic develops a platform of cutting-edge intranasal solutions based on a proprietary know-how in drug-eluting, long-acting, resorbable polymer inserts. Based on state-of-the-art academic research, we collaborate with renowned physicians in order to change the treatment paradigm for debilitating diseases.
Pipeline
Discover our complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.
Three programs. Three stages of development. One platform. Built on DIAXX, our pipeline addresses chronic respiratory diseases (DIA01-R, Phase I-ready in 2026; DIA02-S, preclinical) and central nervous system disorders (DIA03-NTB, discovery), targeting more than 2 billion patients worldwide.
Partner with us
Our drug-enabling platform offers a compelling Lifecycle Management value proposition for pharmaceutical partners via co-development activities — de-risking your formulation work, preclinical in vivo activities and ensuring Phase I readiness.
News
See all news
